MiNK Therapeutics (INKT)

• Market cap: $52.3M
• 1 day: -0.85%
• 5 days: -6.67%
• 1 month: -10.18%
• 3 months: -13.93%
• 6 months: -9.64%
• Year to date: -5.58%
• 1 year: -30.74%
• 5 years: -91.25%
• 10 years: -91.25%
• Sector: Healthcare
• Industry: Biotechnology

About: MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.

Employees: 15